Rituximab Biosimilars Market 2022: Industry Size, Emerging Trends, Growth Insights, Opportunities, and Forecast By 2028
Rituximab Biosimilars Market 2022: Industry Size, Emerging Trends, Growth Insights, Opportunities, and Forecast By 2028
The research report on ‘Rituximab Biosimilars Market’ provides a workplan for stakeholders for the estimated timeframe of -. To elaborate, it offers valid predictions for the size, shares, and growth patterns of this domain over the projected timeline by assessing the past records and present business trends.
Exclusive deal : 20% Instant discount on Direct purchases! Don't wait—claim your discount today!
This report aims to provide a comprehensive presentation of the global market for Rituximab Biosimilars study by Market Intellix gives insights concerning the market elements influencing the market, Market scope, Market division, and overlays shadow upon the leading market players featuring the positive cutthroat scene and patterns beating the years.
Global Rituximab Biosimilars Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global Rituximab Biosimilars Market Sales, 2017-2022, 2023-2028, (K Units)
Global top five Rituximab Biosimilars companies in 2021 (%)
The global Rituximab Biosimilars market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period 2022-2028.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
500mg Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Rituximab Biosimilars include Amgen, AryoGen Pharmed, Biocad, Cadila Pharmaceuticals, Celltrion, Dr Reddy’s Laboratories, Teva, Hetero Group and Innovent Biologics, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
The study provides the Rituximab Biosimilars manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Segmental Outline:
Global Rituximab Biosimilars Market, by Type, 2017-2022, 2023-2028 ($ Millions) & (K Units)
Global Rituximab Biosimilars Market Segment Percentages, by Type, 2021 (%)
500mg
100mg
Other
Global Rituximab Biosimilars Market, by Application, 2017-2022, 2023-2028 ($ Millions) & (K Units)
Global Rituximab Biosimilars Market Segment Percentages, by Application, 2021 (%)
Hospital Pharmacy
Retail Pharmacy
Global Rituximab Biosimilars Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions) & (K Units)
Global Rituximab Biosimilars Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Rituximab Biosimilars revenues in global market, 2017-2022 (Estimated), ($ millions)
Key companies Rituximab Biosimilars revenues share in global market, 2021 (%)
Key companies Rituximab Biosimilars sales in global market, 2017-2022 (Estimated), (K Units)
Key companies Rituximab Biosimilars sales share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
Amgen
AryoGen Pharmed
Biocad
Cadila Pharmaceuticals
Celltrion
Dr Reddy’s Laboratories
Teva
Hetero Group
Innovent Biologics
Intas Biopharmaceuticals
Mylan
Probiomed
TRPharma
Zenotech Laboratories
This Report Addresses:
– Market Intelligence enables effective decision-making
– Market estimates and forecasts from 2022 to 2028
– Growth opportunities and trend analysis
– Segment and regional revenue forecast for market evaluation
– Competitive strategy and analysis of market segments
– List of product innovations to stay on top.
– The impact of COVID-19 and how to survive in these fast-growing markets.
1 Introduction to Research & Analysis Reports
1.1 Rituximab Biosimilars Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Rituximab Biosimilars Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Rituximab Biosimilars Overall Market Size
2.1 Global Rituximab Biosimilars Market Size: 2021 VS 2028
2.2 Global Rituximab Biosimilars Revenue, Prospects & Forecasts: 2017-2028
2.3 Global Rituximab Biosimilars Sales: 2017-2028
3 Company Landscape
3.1 Top Rituximab Biosimilars Players in Global Market
3.2 Top Global Rituximab Biosimilars Companies Ranked by Revenue
3.3 Global Rituximab Biosimilars Revenue by Companies
3.4 Global Rituximab Biosimilars Sales by Companies
3.5 Global Rituximab Biosimilars Price by Manufacturer (2017-2022)
3.6 Top 3 and Top 5 Rituximab Biosimilars Companies in Global Market, by Revenue in 2021
3.7 Global Manufacturers Rituximab Biosimilars Product Type
3.8 Tier 1, Tier 2 and Tier 3 Rituximab Biosimilars Players in Global Market
3.8.1 List of Global Tier 1 Rituximab Biosimilars Companies
3.8.2 List of Global Tier 2 and Tier 3 Rituximab Biosimilars Companies
4 Sights by Product
4.1 Overview
4.1.1 By Type - Global Rituximab Biosimilars Market Size Markets, 2021 & 2028
4.1.2 500mg
4.1.3 100mg
4.1.4 Other
4.2 By Type - Global Rituximab Biosimilars Revenue & Forecasts
4.2.1 By Type - Global Rituximab Biosimilars Revenue, 2017-2022
4.2.2 By Type - Global Rituximab Biosimilars Revenue, 2023-2028
4.2.3 By Type - Global Rituximab Biosimilars Revenue Market Share, 2017-2028
4.3 By Type - Global Rituximab Biosimilars Sales & Forecasts
4.3.1 By Type - Global Rituximab Biosimilars Sales, 2017-2022
4.3.2 By Type - Global Rituximab Biosimilars Sales, 2023-2028
4.3.3 By Type - Global Rituximab Biosimilars Sales Market Share, 2017-2028
4.4 By Type - Global Rituximab Biosimilars Price (Manufacturers Selling Prices), 2017-2028
5 Sights By Application
5.1 Overview
5.1.1 By Application - Global Rituximab Biosimilars Market Size, 2021 & 2028
5.1.2 Hospital Pharmacy
5.1.3 Retail Pharmacy
5.2 By Application - Global Rituximab Biosimilars Revenue & Forecasts
5.2.1 By Application - Global Rituximab Biosimilars Revenue, 2017-2022
5.2.2 By Application - Global Rituximab Biosimilars Revenue, 2023-2028
5.2.3 By Application - Global Rituximab Biosimilars Revenue Market Share, 2017-2028
5.3 By Application - Global Rituximab Biosimilars Sales & Forecasts
5.3.1 By Application - Global Rituximab Biosimilars Sales, 2017-2022
5.3.2 By Application - Global Rituximab Biosimilars Sales, 2023-2028
5.3.3 By Application - Global Rituximab Biosimilars Sales Market Share, 2017-2028
5.4 By Application - Global Rituximab Biosimilars Price (Manufacturers Selling Prices), 2017-2028
6 Sights by Region
6.1 By Region - Global Rituximab Biosimilars Market Size, 2021 & 2028
6.2 By Region - Global Rituximab Biosimilars Revenue & Forecasts
6.2.1 By Region - Global Rituximab Biosimilars Revenue, 2017-2022
6.2.2 By Region - Global Rituximab Biosimilars Revenue, 2023-2028
6.2.3 By Region - Global Rituximab Biosimilars Revenue Market Share, 2017-2028
6.3 By Region - Global Rituximab Biosimilars Sales & Forecasts
6.3.1 By Region - Global Rituximab Biosimilars Sales, 2017-2022
6.3.2 By Region - Global Rituximab Biosimilars Sales, 2023-2028
6.3.3 By Region - Global Rituximab Biosimilars Sales Market Share, 2017-2028
6.4 North America
6.4.1 By Country - North America Rituximab Biosimilars Revenue, 2017-2028
6.4.2 By Country - North America Rituximab Biosimilars Sales, 2017-2028
6.4.3 US Rituximab Biosimilars Market Size, 2017-2028
6.4.4 Canada Rituximab Biosimilars Market Size, 2017-2028
6.4.5 Mexico Rituximab Biosimilars Market Size, 2017-2028
6.5 Europe
6.5.1 By Country - Europe Rituximab Biosimilars Revenue, 2017-2028
6.5.2 By Country - Europe Rituximab Biosimilars Sales, 2017-2028
6.5.3 Germany Rituximab Biosimilars Market Size, 2017-2028
6.5.4 France Rituximab Biosimilars Market Size, 2017-2028
6.5.5 U.K. Rituximab Biosimilars Market Size, 2017-2028
6.5.6 Italy Rituximab Biosimilars Market Size, 2017-2028
6.5.7 Russia Rituximab Biosimilars Market Size, 2017-2028
6.5.8 Nordic Countries Rituximab Biosimilars Market Size, 2017-2028
6.5.9 Benelux Rituximab Biosimilars Market Size, 2017-2028
6.6 Asia
6.6.1 By Region - Asia Rituximab Biosimilars Revenue, 2017-2028
6.6.2 By Region - Asia Rituximab Biosimilars Sales, 2017-2028
6.6.3 China Rituximab Biosimilars Market Size, 2017-2028
6.6.4 Japan Rituximab Biosimilars Market Size, 2017-2028
6.6.5 South Korea Rituximab Biosimilars Market Size, 2017-2028
6.6.6 Southeast Asia Rituximab Biosimilars Market Size, 2017-2028
6.6.7 India Rituximab Biosimilars Market Size, 2017-2028
6.7 South America
6.7.1 By Country - South America Rituximab Biosimilars Revenue, 2017-2028
6.7.2 By Country - South America Rituximab Biosimilars Sales, 2017-2028
6.7.3 Brazil Rituximab Biosimilars Market Size, 2017-2028
6.7.4 Argentina Rituximab Biosimilars Market Size, 2017-2028
6.8 Middle East & Africa
6.8.1 By Country - Middle East & Africa Rituximab Biosimilars Revenue, 2017-2028
6.8.2 By Country - Middle East & Africa Rituximab Biosimilars Sales, 2017-2028
6.8.3 Turkey Rituximab Biosimilars Market Size, 2017-2028
6.8.4 Israel Rituximab Biosimilars Market Size, 2017-2028
6.8.5 Saudi Arabia Rituximab Biosimilars Market Size, 2017-2028
6.8.6 UAE Rituximab Biosimilars Market Size, 2017-2028
7 Manufacturers & Brands Profiles
7.1 Amgen
7.1.1 Amgen Corporate Summary
7.1.2 Amgen Business Overview
7.1.3 Amgen Rituximab Biosimilars Major Product Offerings
7.1.4 Amgen Rituximab Biosimilars Sales and Revenue in Global (2017-2022)
7.1.5 Amgen Key News
7.2 AryoGen Pharmed
7.2.1 AryoGen Pharmed Corporate Summary
7.2.2 AryoGen Pharmed Business Overview
7.2.3 AryoGen Pharmed Rituximab Biosimilars Major Product Offerings
7.2.4 AryoGen Pharmed Rituximab Biosimilars Sales and Revenue in Global (2017-2022)
7.2.5 AryoGen Pharmed Key News
7.3 Biocad
7.3.1 Biocad Corporate Summary
7.3.2 Biocad Business Overview
7.3.3 Biocad Rituximab Biosimilars Major Product Offerings
7.3.4 Biocad Rituximab Biosimilars Sales and Revenue in Global (2017-2022)
7.3.5 Biocad Key News
7.4 Cadila Pharmaceuticals
7.4.1 Cadila Pharmaceuticals Corporate Summary
7.4.2 Cadila Pharmaceuticals Business Overview
7.4.3 Cadila Pharmaceuticals Rituximab Biosimilars Major Product Offerings
7.4.4 Cadila Pharmaceuticals Rituximab Biosimilars Sales and Revenue in Global (2017-2022)
7.4.5 Cadila Pharmaceuticals Key News
7.5 Celltrion
7.5.1 Celltrion Corporate Summary
7.5.2 Celltrion Business Overview
7.5.3 Celltrion Rituximab Biosimilars Major Product Offerings
7.5.4 Celltrion Rituximab Biosimilars Sales and Revenue in Global (2017-2022)
7.5.5 Celltrion Key News
7.6 Dr Reddy’s Laboratories
7.6.1 Dr Reddy’s Laboratories Corporate Summary
7.6.2 Dr Reddy’s Laboratories Business Overview
7.6.3 Dr Reddy’s Laboratories Rituximab Biosimilars Major Product Offerings
7.6.4 Dr Reddy’s Laboratories Rituximab Biosimilars Sales and Revenue in Global (2017-2022)
7.6.5 Dr Reddy’s Laboratories Key News
7.7 Teva
7.7.1 Teva Corporate Summary
7.7.2 Teva Business Overview
7.7.3 Teva Rituximab Biosimilars Major Product Offerings
7.7.4 Teva Rituximab Biosimilars Sales and Revenue in Global (2017-2022)
7.7.5 Teva Key News
7.8 Hetero Group
7.8.1 Hetero Group Corporate Summary
7.8.2 Hetero Group Business Overview
7.8.3 Hetero Group Rituximab Biosimilars Major Product Offerings
7.8.4 Hetero Group Rituximab Biosimilars Sales and Revenue in Global (2017-2022)
7.8.5 Hetero Group Key News
7.9 Innovent Biologics
7.9.1 Innovent Biologics Corporate Summary
7.9.2 Innovent Biologics Business Overview
7.9.3 Innovent Biologics Rituximab Biosimilars Major Product Offerings
7.9.4 Innovent Biologics Rituximab Biosimilars Sales and Revenue in Global (2017-2022)
7.9.5 Innovent Biologics Key News
7.10 Intas Biopharmaceuticals
7.10.1 Intas Biopharmaceuticals Corporate Summary
7.10.2 Intas Biopharmaceuticals Business Overview
7.10.3 Intas Biopharmaceuticals Rituximab Biosimilars Major Product Offerings
7.10.4 Intas Biopharmaceuticals Rituximab Biosimilars Sales and Revenue in Global (2017-2022)
7.10.5 Intas Biopharmaceuticals Key News
7.11 Mylan
7.11.1 Mylan Corporate Summary
7.11.2 Mylan Rituximab Biosimilars Business Overview
7.11.3 Mylan Rituximab Biosimilars Major Product Offerings
7.11.4 Mylan Rituximab Biosimilars Sales and Revenue in Global (2017-2022)
7.11.5 Mylan Key News
7.12 Probiomed
7.12.1 Probiomed Corporate Summary
7.12.2 Probiomed Rituximab Biosimilars Business Overview
7.12.3 Probiomed Rituximab Biosimilars Major Product Offerings
7.12.4 Probiomed Rituximab Biosimilars Sales and Revenue in Global (2017-2022)
7.12.5 Probiomed Key News
7.13 TRPharma
7.13.1 TRPharma Corporate Summary
7.13.2 TRPharma Rituximab Biosimilars Business Overview
7.13.3 TRPharma Rituximab Biosimilars Major Product Offerings
7.13.4 TRPharma Rituximab Biosimilars Sales and Revenue in Global (2017-2022)
7.13.5 TRPharma Key News
7.14 Zenotech Laboratories
7.14.1 Zenotech Laboratories Corporate Summary
7.14.2 Zenotech Laboratories Business Overview
7.14.3 Zenotech Laboratories Rituximab Biosimilars Major Product Offerings
7.14.4 Zenotech Laboratories Rituximab Biosimilars Sales and Revenue in Global (2017-2022)
7.14.5 Zenotech Laboratories Key News
8 Global Rituximab Biosimilars Production Capacity, Analysis
8.1 Global Rituximab Biosimilars Production Capacity, 2017-2028
8.2 Rituximab Biosimilars Production Capacity of Key Manufacturers in Global Market
8.3 Global Rituximab Biosimilars Production by Region
9 Key Market Trends, Opportunity, Drivers and Restraints
9.1 Market Opportunities & Trends
9.2 Market Drivers
9.3 Market Restraints
10 Rituximab Biosimilars Supply Chain Analysis
10.1 Rituximab Biosimilars Industry Value Chain
10.2 Rituximab Biosimilars Upstream Market
10.3 Rituximab Biosimilars Downstream and Clients
10.4 Marketing Channels Analysis
10.4.1 Marketing Channels
10.4.2 Rituximab Biosimilars Distributors and Sales Agents in Global
11 Conclusion
12 Appendix
12.1 Note
12.2 Examples of Clients
12.3 Disclaimer
Research Methodology:
Rituximab Biosimilars Market Size Estimation
To estimate market size and trends, we use a combination of top-down and bottom-up methods. This allows us to evaluate the market from various perspectives—by company, region, product type, and end users.
Our estimates are based on actual sales data, excluding any discounts. Segment breakdowns and market shares are calculated using weighted averages based on usage rates and average prices. Regional insights are determined by how widely a product or service is adopted in each area.
Key companies are identified through secondary sources like industry reports and company filings. We then verify revenue estimates and other key data points through primary research, including interviews with industry experts, company executives, and decision-makers.
We take into account all relevant factors that could influence the market and validate our findings with real-world input. Our final insights combine both qualitative and quantitative data to provide a well-rounded view. Please note, these estimates do not account for unexpected changes such as inflation, economic downturns, or policy shifts.
Data Source
Secondary Sources
This study draws on a wide range of secondary sources, including press releases, annual reports, non-profit organizations, industry associations, government agencies, and customs data. We also referred to reputable databases and directories such as Bloomberg, Wind Info, Hoovers, Factiva, Trading Economics, Statista, and others. Additional references include investor presentations, company filings (e.g., SEC), economic data, and documents from regulatory and industry bodies.
These sources were used to gather technical and market-focused insights, identify key players, analyze market segmentation and classification, and track major trends and developments across industries.
| Market Size |
|
|
| Market Position of Top Company |
|
|
| Qualitative Analysis |
|
|
Primary Sources
As part of our primary research, we interviewed a variety of stakeholders from both the supply and demand sides to gather valuable qualitative and quantitative insights.
On the supply side, we spoke with product manufacturers, competitors, industry experts, research institutions, distributors, traders, and raw material suppliers. On the demand side, we engaged with business leaders, marketing and sales heads, technology and innovation directors, supply chain executives, and end users across key organizations.
These conversations helped us better understand market segmentation, pricing, applications, leading players, supply chains, demand trends, industry outlook, and key market dynamics—including risks, opportunities, barriers, and strategic developments.
Key Data Information from Primary Sources
| Primary Sources | Parameters | Key Data |
| Market Segments(by Application, by Type) |
|
|
| Total Market |
|
|